501008-39-5

Basic information

• Product Name: ethyl 2-((3,5-dichlorophenyl)amino)acetate
• Synonyms: ethyl 2-((3,5-dichlorophenyl)amino)acetate
• CAS NO: 501008-39-5
• Molecular Weight: 248.109
• Mol File: 501008-39-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 2-((3,5-dichlorophenyl)amino)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-((3,5-dichlorophenyl)amino)acetate(501008-39-5)
• EPA Substance Registry System: ethyl 2-((3,5-dichlorophenyl)amino)acetate(501008-39-5)

Safety Data

• Hazardous Substances Data: 501008-39-5(Hazardous Substances Data)

Upstream product

• 105-36-2 ethyl bromoacetate 
• 626-43-7 3,5-Dichloroaniline 

Downstream Products

• 1419030-74-2 C₁₁H₁₁Cl₂NO 
• 1225761-30-7 N-allyl-3,5-dichloroaniline 
• 1419030-78-6 ethyl 2-(allyl(3,5-dichlorophenyl)amino)acetate 
• 42288-29-9 2-((3,5-dichlorophenyl)arnino)acetic acid 
• 1426318-90-2 ethyl (2R,3S)-2-(3,5-dichlorophenylamino)-3-hydroxy-4-oxo-4-phenylbutanoate 

Relevant articles and documents

A novel synthesis of 1-aryl-3-piperidone derivatives

A novel method to construct the 1-aryl-3-piperidone scaffold is described here. Starting from 3,5-dichloroaniline, a seven-step synthesis, without the use of protecting groups, generates the desired 3-piperidone ring in an overall yield of 30% through a key Morita-Baylis-Hillman reaction and ring-closing metathesis, providing easy access to diverse and useful heterocycles.

Arylamino containing hydroxamic acids as potent urease inhibitors for the treatment of Helicobacter pylori infection

A novel series of aniline-containing hydroxamic acids were designed, synthesized and evaluated as anti-virulence agents for the treatment of gastritis and gastric ulcer caused by Helicobacter pylori. In vitro enzyme-based screen together with in vivo assays and structure?activity relationship (SAR) studies led to the discovery of three potent urease inhibitors 3-(3,5-dichlorophenylamino)–N-hydroxypropanamide (3a), 3-(2-chlorophenylamino)–N-hydroxypropanamide (3d) and 3-(2,4-dichlorophenylamino)–N-hydroxypropanamide (3n). Compounds 3a, 3d and 3n showed excellent urease inhibition with IC50 values 0.043 ± 0.005, 0.055 ± 0.008 and 0.018 ± 0.002 μM, and significantly depressed gastritis developing at the dose of 32 mg/kg b. i.d with eradication rates of H. pylori reaching 92.3, 84.6 and 100%, respectively. Preliminary safety studies (acute toxicity in mice) disclosed that 3a, 3d and 3n was well-tolerated in KM mice with LD50s of 2982.8, 3349.4 and 3126.9 mg/kg, respectively. Collectively, the data obtained in this study indicate that 3a, 3d and 3n, in particular 3n, could considered as promising candidates for the potential treatment of H. pylori caused gastritis and gastric ulcer, and hence merit further studies.